Endolysosomal Degradation Avoidance
Endolysosomal Degradation Avoidance is a strategic mechanism in intracellular delivery systems that enables therapeutic agents to circumvent degradation within the endolysosomal pathway by preventing or escaping fusion with lysosomes, thereby ensuring cargo bioavailability in the cytoplasm.
10
Publications
664
Citations
75
Authors
32
Institutions
Publications per year
2017–2026
7
Parents
10
1–5 of 10
75
1
h-index
1
h-index
1
h-index
1
h-index
1
h-index
1–5 of 75
32
Rutgers Cancer Institute
New Brunswick, United States
1 h-index
3 publications
132 citations
Luye Pharma (China)
Shanghai, China
1 h-index
1 publications
12 citations

Imperial College London
London, United Kingdom
1 h-index
9 publications
396 citations

Chiang Mai University
Chiang Mai, Thailand
1 h-index
2 publications
88 citations
Nanjing University
Nanjing, China
1 h-index
9 publications
1.1K citations

Nantes Université
Nantes, France
1 h-index
1 publications
143 citations
Optical Sciences (United States)
Huntsville, United States
1 h-index
4 publications
512 citations
UCLouvain
Louvain-la-Neuve, Belgium
1 h-index
1 publications
58 citations
1–8 of 32
2 publications · 163 citations
2
h-index
1 publications · 65 citations
1
h-index
JACS · 1 publications · 127 citations
1
h-index
PNAS · 1 publications · 44 citations
1
h-index
1 publications · 15 citations
1
h-index
1–5